ACM
SWTX

AlphaCrest Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

AlphaCrest Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,300
Closed -$519K – 1378
2021
Q2 		$519K Buy
+6,300
New +$478K 0.02% 945

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AlphaCrest Capital Management's SWTX Position: Q3 2021 in Review

AlphaCrest Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2021, closing a stake of 6,300 shares — an estimated $519K sold.

AlphaCrest Capital Management first reported a position in SWTX in Q2 2021 and held it in 1 quarter. The position peaked at $519K in Q2 2021. 142 funds tracked by Wall St. Rank hold SWTX as of Q3 2021.

  • AlphaCrest Capital Management reported no remaining SpringWorks Therapeutics position as of Q3 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 6,300 SpringWorks Therapeutics shares in Q3 2021, an estimated $519K.
  • AlphaCrest Capital Management first reported a position in SpringWorks Therapeutics in Q2 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's SpringWorks Therapeutics position peaked at $519K in Q2 2021.
  • 142 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2021.

Based on AlphaCrest Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.